Novocare Wegovy infographic showing self-pay prices and program features

New Novocare for Wegovy: Free Membership, Home Delivery and $149 to $399 Prices Explained

Novocare Wegovy members can now sign up for a free, redesigned program that Novo Nordisk launched on 17 November 2026, bundling prescription fills, home delivery, coverage checks and partner services such as WHOOP and Factor around its obesity drug. Home delivery runs today for self-pay patients, and Novo says it will extend to eligible people with commercial or government insurance, including Medicare Bridge, in the coming weeks, with a points-based rewards scheme due by year-end.

Key takeaways on Novocare Wegovy

  • Novocare is now a free membership with a new website and app at JoinNovocare.com, covering both the Wegovy injection and the Wegovy pill.
  • Self-pay Wegovy injection costs $349 a month for most doses ($399 for the 7.2 mg dose), with a $199 introductory price for the first two monthly fills for new patients through 31 December 2026.
  • Self-pay Wegovy pill prices run from $149 a month (1.5 mg) to $299 (9 mg and 25 mg).
  • Four outside partners are live: WHOOP, Berry Street, Factor and Stitch Fix. Their services cost extra and have their own eligibility rules.
  • Delivery for insured patients and the Novocare Points rewards program are announced but not yet live.

What actually changed for Wegovy patients

Novo has run a NovoCare cash-pay pharmacy for some time. The relaunch turns it into a membership hub that tries to handle the whole patient journey in one place. According to the Novo Nordisk announcement, members can compare injection and pill options, see self-pay and insurance offers, prepare for a conversation with their prescriber, fill and refill prescriptions, and get phone or live-chat help.

One practical detail stands out. If an insurer requires prior authorization, Novocare can work with the prescriber and the plan while the patient starts on self-pay in the meantime. That addresses a familiar problem: people with a valid prescription waiting weeks for paperwork before a first dose.

The program also layers on health education, community coaching and progress tracking. Novo described the aim as “helping people get started on treatment and stay supported”, which is a nod to the persistence problem that has dogged GLP-1 therapy, where many patients stop within the first year.

How much Wegovy costs through Novocare

The launch release itself lists no prices. The figures below come from Novo’s own Wegovy cost and savings page as of 17 November 2026. Annual figures are by our calculation and assume 12 monthly fills at the standard price.

Wegovy form and doseSelf-pay per monthPer year (by our calculation)
Injection 0.25 mg to 2.4 mg (4 pens)$349$4,188
Injection 7.2 mg (Wegovy HD)$399$4,788
Injection, new patient intro (first 2 fills)$199$3,888 in year one if both intro fills are used
Pill 1.5 mg (30 tablets)$149$1,788
Pill 4 mg$199$2,388
Pill 9 mg or 25 mg$299$3,588

Two caveats matter. Novo notes that self-pay amounts do not count toward a deductible or out-of-pocket maximum, and that it can change or end the offers at any time. The lower pill prices apply to starting doses, so most people titrating to a maintenance dose will end up nearer the top of the range. For comparison, a recent CVS Health analysis we covered found that GLP-1 drugs break even for payers below about $350 a month, which is roughly where Wegovy’s cash price now sits.

Who gets home delivery now, and who waits

Home delivery currently covers the self-pay program only. Novo says delivery will widen to eligible members with commercial insurance or government coverage, including Medicare Bridge, “in the coming weeks” but gave no firm date. Ozempic home delivery continues for eligible prescriptions. Medical eligibility is unchanged: the injection is approved for adults and children aged 12 and over with obesity, and for some adults with overweight plus a weight-related condition, while the tablet is for adults only. Both forms also carry a cardiovascular risk-reduction indication in adults with established heart disease and obesity or overweight.

The partner lineup, and what it does not include

Four third-party partners are listed as live: WHOOP for wearable health tracking, Berry Street for registered dietitian guidance, Factor for prepared meals, and Stitch Fix for personal styling aimed at people whose clothing size is changing. These are referrals, not included services. Each has its own price and terms, and Novo says more partners are planned. Novocare Points, which members will earn through selected activities and spend on partner offers, is slated for launch by year-end, with terms still to be published.

Our read: the partner list is mostly about retention. Muscle preservation, nutrition and keeping patients engaged past the first few months are the areas where GLP-1 programs most often fall down, and a meal service plus a wearable target exactly those. Whether a rewards program changes long-term adherence is unproven.

Why Novo is doubling down on direct-to-patient

The relaunch lands in an intensely competitive cash market. Eli Lilly sells Zepbound through its own direct channel and has expanded through telehealth partners, as seen in Lilly’s Zepbound deal with Hims & Hers. Compounded semaglutide has also pulled patients away from branded supply. A free, sticky membership that owns the patient relationship, rather than routing them through a third-party telehealth brand, gives Novo direct data on persistence and a way to steer people between its pen and pill.

Safety still applies, whatever the channel

Easier access does not change the drug’s risk profile. Wegovy carries a boxed warning on thyroid C-cell tumors seen in rodents and should not be used by people with a personal or family history of medullary thyroid carcinoma or MEN 2. Other listed risks include pancreatitis, gallbladder disease, kidney problems from dehydration and aspiration during anesthesia. This month the FDA also added a NAION eye warning to all GLP-1 drugs. Treatment decisions belong with a prescriber.

Market context

Programs like Novocare sit where drugs meet digital care. According to Acumen Research and Consulting, the global digital health for obesity market was worth USD 48.1 billion in 2023 and is projected to reach USD 276.5 billion by 2032, a 21.7% compound annual growth rate from 2024. Acumen finds services are the largest component and North America the dominant region, with Asia-Pacific growing fastest. Manufacturer-run platforms that combine prescriptions, coaching and wearables are one reason that services segment keeps expanding.

Frequently asked questions

Is Novocare free to join?

Yes. Membership is free. You still pay for Wegovy itself, either through insurance or the self-pay prices, and partner services such as Factor or WHOOP are charged separately.

How much is Wegovy without insurance through Novocare?

Most injection doses are $349 a month and the 7.2 mg dose is $399. New patients can pay $199 for each of their first two monthly fills through 31 December 2026. The pill costs $149 to $299 a month depending on dose.

Can I use Novocare home delivery with insurance?

Not yet. Delivery is self-pay only today. Novo says eligible commercial and government-insured members, including Medicare Bridge, will be added in the coming weeks.

Do I still need a prescription?

Yes. Novocare fills prescriptions from a licensed prescriber. It helps with information, coverage and delivery but does not replace a medical evaluation.

More coverage: Pharmaceutical news on MedGadget.

Sources: Novo Nordisk press release (17 November 2026); NovoCare Wegovy cost page. Market data: Acumen Research and Consulting, Digital Health for Obesity Market report. This article is for information only and is not medical or investment advice. Last updated 17 November 2026.

Leave a Comment

Comments

No comments yet. Why don’t you start the discussion?

    Leave a Reply

    Your email address will not be published. Required fields are marked *